Engineering protein-based therapeutics through structural and chemical design

Abstract Protein-based therapeutics have led to new paradigms in disease treatment. Projected to be half of the top ten selling drugs in 2023, proteins have emerged as rivaling and, in some cases, superior alternatives to historically used small molecule-based medicines. This review chronicles both...

Full description

Bibliographic Details
Main Authors: Sasha B. Ebrahimi, Devleena Samanta
Format: Article
Language:English
Published: Nature Portfolio 2023-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-38039-x
_version_ 1797836330415161344
author Sasha B. Ebrahimi
Devleena Samanta
author_facet Sasha B. Ebrahimi
Devleena Samanta
author_sort Sasha B. Ebrahimi
collection DOAJ
description Abstract Protein-based therapeutics have led to new paradigms in disease treatment. Projected to be half of the top ten selling drugs in 2023, proteins have emerged as rivaling and, in some cases, superior alternatives to historically used small molecule-based medicines. This review chronicles both well-established and emerging design strategies that have enabled this paradigm shift by transforming protein-based structures that are often prone to denaturation, degradation, and aggregation in vitro and in vivo into highly effective therapeutics. In particular, we discuss strategies for creating structures with increased affinity and targetability, enhanced in vivo stability and pharmacokinetics, improved cell permeability, and reduced amounts of undesired immunogenicity.
first_indexed 2024-04-09T15:08:12Z
format Article
id doaj.art-1d6a307e66504e2fa9508dacdfbe4bb3
institution Directory Open Access Journal
issn 2041-1723
language English
last_indexed 2024-04-09T15:08:12Z
publishDate 2023-04-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj.art-1d6a307e66504e2fa9508dacdfbe4bb32023-04-30T11:21:28ZengNature PortfolioNature Communications2041-17232023-04-0114111110.1038/s41467-023-38039-xEngineering protein-based therapeutics through structural and chemical designSasha B. Ebrahimi0Devleena Samanta1Drug Product Development—Steriles, GlaxoSmithKlineDepartment of Chemistry, The University of Texas at AustinAbstract Protein-based therapeutics have led to new paradigms in disease treatment. Projected to be half of the top ten selling drugs in 2023, proteins have emerged as rivaling and, in some cases, superior alternatives to historically used small molecule-based medicines. This review chronicles both well-established and emerging design strategies that have enabled this paradigm shift by transforming protein-based structures that are often prone to denaturation, degradation, and aggregation in vitro and in vivo into highly effective therapeutics. In particular, we discuss strategies for creating structures with increased affinity and targetability, enhanced in vivo stability and pharmacokinetics, improved cell permeability, and reduced amounts of undesired immunogenicity.https://doi.org/10.1038/s41467-023-38039-x
spellingShingle Sasha B. Ebrahimi
Devleena Samanta
Engineering protein-based therapeutics through structural and chemical design
Nature Communications
title Engineering protein-based therapeutics through structural and chemical design
title_full Engineering protein-based therapeutics through structural and chemical design
title_fullStr Engineering protein-based therapeutics through structural and chemical design
title_full_unstemmed Engineering protein-based therapeutics through structural and chemical design
title_short Engineering protein-based therapeutics through structural and chemical design
title_sort engineering protein based therapeutics through structural and chemical design
url https://doi.org/10.1038/s41467-023-38039-x
work_keys_str_mv AT sashabebrahimi engineeringproteinbasedtherapeuticsthroughstructuralandchemicaldesign
AT devleenasamanta engineeringproteinbasedtherapeuticsthroughstructuralandchemicaldesign